Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × ipatasertib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 2 OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Stomach Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Adenocarcinoma 1

Interventions

Docetaxel 153 Magnetic Resonance Spectroscopy 124 Radiotherapy 123 Prednisone 98 Leuprolide 98 Radiosurgery 92 enzalutamide 91 Abiraterone Acetate 81 Androgen Antagonists 80 Goserelin 72 bicalutamide 68 gallium 68 PSMA-11 59 Specimen Handling 53 Surveys and Questionnaires 52 apalutamide 51 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51 Radiation 42 Biopsy 42 Brachytherapy 40 Gonadotropin-Releasing Hormone 39 Standard of Care 37 abiraterone 36 Blood Specimen Collection 35 darolutamide 34 cabazitaxel 34 Exercise 33 Radiotherapy, Intensity-Modulated 32 Carboplatin 31 Triptorelin Pamoate 28 Pluvicto 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04737109 2023-11-13

ADDItion

Big Ten Cancer Research Consortium

Phase 1/2 Terminated

6 enrolled 9 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡